Hair loss–focused Veradermics and cancer biotech Eikon follow the lead of Aktis Oncology, which last week announced a $318 million IPO target.

The two IPOs, which follow radiopharma specialist Aktis Oncology's filing last week, have investors and industry watchers speculating about a return of a buoyant biotech IPO environment after a ...

Eikon Therapeutics Inc. filed for an initial public offering to help fund its advanced pipeline of cancer drugs.

Eikon Therapeutics, Inc. eyes IPO to fund EIK1001 oncology pipeline; early Phase 2 data show 60% response rate. Click for ...

Biotechnology company Eikon Therapeutics announced the initial closing of a $350.7 million Series D financing round that it will use to advance its clinical-stage programs. The new funding brings the ...

Jan 9 (Reuters) - Clinical biopharmaceutical company Eikon Therapeutics on Friday filed for an initial public offering in the United States. Eikon Therapeutics is a late-stage clinical ...

Eikon Therapeutics, the drug discovery startup with a former Merck & Co. research chief at the helm, has appointed a pantheon of biotech veterans on its quest to take its live-cell imaging platform to ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Eikon Therapeutics, a well-funded drug startup run by ...

Eikon Therapeutics is planning to become the second biotech to go public in 2026 in another sign the public markets are looking increasingly attractive to drug developers. Eikon emerged publicly in ...